{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000062","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.247514+00:00","generated_at":"2026-05-30T08:07:43.566367+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours","bullets":["SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.","By Day 10, response rate improved to 84.2% and remission to 63.2% in adults with major depressive disorder.","Company notes positive early data; continues development and discussions with potential partners for Sunseeker asset."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000062","json":"https://secwatch.observer/filing/0001356576-24-000062.json","markdown":"https://secwatch.observer/filing/0001356576-24-000062.md","text":"https://secwatch.observer/filing/0001356576-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/0001356576-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/supn-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:07:43.566367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}